Vaxart, Inc.

How big is Vaxart, Inc.?

As of Jun 18, Vaxart, Inc. has a market capitalization of 136.00 million and reported net sales of 47.40 million with a net profit of -58.12 million over the latest four quarters. Shareholder's funds are 58.92 million, and total assets amount to 166.39 million.

As of Jun 18, Vaxart, Inc. has a market capitalization of 136.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 47.40 million, while the sum of net profit for the same period is -58.12 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 58.92 million, and the total assets amount to 166.39 million.

What does Vaxart, Inc. do?

Vaxart, Inc. is a micro-cap biotechnology company focused on developing direct-acting antivirals for infections. As of March 2025, it reported net sales of $21 million and a net loss of $16 million, with a market cap of $136 million.

Overview: <BR>Vaxart, Inc. is focused on the discovery and development of direct-acting antivirals to treat infections, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 136.00 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -127.41% <BR>Price to Book: 2.98<BR><BR>Contact Details: <BR>Address: 385 Oyster Point Boulevard, Suite 9A, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 650 5503500 <BR>Fax: 1 650 8718580 <BR>Website: https://vaxart.com/

Should I buy, sell or hold Vaxart, Inc.?

Who are in the management team of Vaxart, Inc.?

As of March 2022, the management team of Vaxart, Inc. includes Dr. Wouter Latour (Chairman), Mr. Andrei Floroiu (CEO), Mr. Robert Yedid (Lead Independent Director), and several other directors. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Vaxart, Inc. includes the following individuals:<BR><BR>- Dr. Wouter Latour, Chairman of the Board<BR>- Mr. Andrei Floroiu, Chief Executive Officer, Principal Financial Officer, and Director<BR>- Mr. Robert Yedid, Lead Independent Director<BR>- Mr. Steven Boyd, Director<BR>- Mr. Keith Maher, Director<BR>- Mr. Todd Davis, Independent Director<BR>- Dr. Michael Finney, Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Is Vaxart, Inc. overvalued or undervalued?

As of August 3, 2023, Vaxart, Inc. is rated as risky and overvalued, with key financial metrics indicating poor performance compared to peers and a year-to-date return of -41.85%, significantly underperforming the S&P 500's 12.22%.

As of 3 August 2023, the valuation grade for Vaxart, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.03, an EV to Sales ratio of 1.22, and a troubling ROCE of -535.64%. <BR><BR>In comparison to peers, Vaxart's EV to EBITDA ratio stands at -1.09, while TScan Therapeutics, Inc. has a ratio of 0.5157, and Prelude Therapeutics, Inc. has a ratio of -0.0018, indicating Vaxart is underperforming relative to its industry counterparts. The stock has significantly lagged behind the S&P 500, with a year-to-date return of -41.85% compared to the index's 12.22%, highlighting its challenging position in the market.

Is Vaxart, Inc. technically bullish or bearish?

As of September 8, 2025, Vaxart, Inc. is in a mildly bearish trend, indicated by daily moving averages and weekly KST, despite some bullish signals from the MACD, while its performance has significantly lagged behind the S&P 500 with a year-to-date decline of 41.85%.

As of 8 September 2025, the technical trend for Vaxart, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend and weekly KST showing bearish momentum. However, the weekly and monthly MACD readings are mildly bullish, suggesting some potential for upward movement. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. <BR><BR>In terms of performance, Vaxart's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date decline of 41.85% compared to the S&P's gain of 12.22%, and a one-year return of -57.23% versus the S&P's 17.14%.